ADC Therapeutics (ADCT) EBIT Margin (2021 - 2026)
ADC Therapeutics' (ADCT) quarterly EBIT Margin came in at 132.03% in Q2 2026, up 10230.0% year-over-year from N/an in Q2 2025, and down 9.05% quarter-over-quarter from 121.07% in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) EBIT Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics has disclosed EBIT Margin across 6 years of filings, most recently posting 132.03% for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -23.56% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.36% |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn | -132.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -132.03% |
| Mar 31, 2026 | -121.07% |
| Sep 30, 2025 | -188.52% |
| Jun 30, 2025 | -234.34% |
| Mar 31, 2025 | -123.58% |
| Sep 30, 2024 | -192.61% |
| Jun 30, 2024 | -166.81% |
| Mar 31, 2024 | -186.19% |
| Sep 30, 2023 | -249.42% |
| Jun 30, 2023 | -205.62% |
| Mar 31, 2023 | -271.55% |
| Sep 30, 2022 | -4.08% |
| Jun 30, 2022 | -401.43% |
| Mar 31, 2022 | -86.81% |
| Sep 30, 2021 | -439.58% |
| Jun 30, 2021 | -1,874.52% |